found that a patient with poorly differentiated LSCC (Case 10 in Table 1) preserved the original genetic alterations after immunotherapy-triggered conversion into SCLC, i.e., TP53 mutation (p. R283fs*62), CDKN2A mutation (R58), SOX2 amplification, and PIK3CA amplification (12). The gene discussed is TP53; the disease is small cell lung carcinoma.